Gastroenterology (all articles)
RCT | Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease.
20 Oct, 2022 | 12:26h | UTCEtrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary: Etrolizumab Increases Chance of Clinical Remission for Crohn’s Disease – HCP Live
Commentary on Twitter
New research – Sandborn et al – Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial https://t.co/I81bEfz5WU#IBD #GITwitter #UEGWeek pic.twitter.com/lwnl1EI7cz
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) October 12, 2022
M-A of RCT | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.
20 Oct, 2022 | 12:25h | UTCCarvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis – Journal of Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
#Carvedilol
➡️non-selective #βblocker
✅associated with reduced risk of decompensating events
➡️improved survival in patients with #cirrhosis & #portalhypertensionRead it here?https://t.co/yy8DIJBhfL#LiverTwitter pic.twitter.com/XxmrB7gff8
— Journal of Hepatology (@JHepatology) October 13, 2022
RCT | Vonoprazan noninferior to Lansoprazole for healing and maintenance of healing of erosive esophagitis.
19 Oct, 2022 | 14:08h | UTC
M-A | Proactive therapeutic drug monitoring vs. conventional management for inflammatory bowel diseases.
18 Oct, 2022 | 12:42h | UTC
Commentary on Twitter
October's Editor's Essential Reading examines proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases @vipuljairath @ChrisMa_YYC https://t.co/kNAia4yowO pic.twitter.com/wfgQSQtM1O
— Gastroenterology (@AGA_Gastro) September 28, 2022
Review | New endoscopic tools in inflammatory bowel disease.
18 Oct, 2022 | 12:40h | UTCNew endoscopic tools in inflammatory bowel disease – UEG Journal
15-year benefits of sigmoidoscopy screening on colorectal cancer incidence and mortality: a pooled analysis of randomized trials.
13 Oct, 2022 | 13:48h | UTC15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: A Pooled Analysis of Randomized Trials – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: One sigmoidoscopy significantly reduces long-term CRC incidence in both men and women – American College of Physicians
Related:
RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
ACP Guideline: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Commentary on Twitter
A pooled analysis evaluating 15-yr effect of sigmoidoscopies found that receiving 1 #sigmoidoscopy significantly reduces long-term incidence of CRC in men and women: https://t.co/QXj5VRMHeo pic.twitter.com/s82sOJmBzr
— Annals of Int Med (@AnnalsofIM) October 11, 2022
Consensus Recommendations | Minimizing the risk of monkeypox virus transmission during fecal microbiota transplantation.
12 Oct, 2022 | 13:54h | UTC
Benefits and risks associated with continuation of anti–TNF after 24 weeks of pregnancy in inflammatory bowel disease.
12 Oct, 2022 | 13:52h | UTCBenefits and Risks Associated With Continuation of Anti–Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Continuation of Anti-TNF for IBD After 24 Weeks of Pregnancy Beneficial – HealthDay
Commentary on Twitter
10 year trial found continuation of #AntiTNF treatment after 24 weeks of pregnancy appears beneficial for #IBD activity and prematurity, not affecting neonatal outcomes and serious infections in the offspring. @EPIPHARE https://t.co/YuytSQqDsE pic.twitter.com/CRGN80K93A
— Annals of Int Med (@AnnalsofIM) September 27, 2022
RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
11 Oct, 2022 | 13:42h | UTCEffect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
In gold-standard trial, invitation to colonoscopy reduced cancer incidence but not death – STAT
New study examines the effectiveness of colonoscopies – CNN
Choosing Wisely | Top five list of procedures to avoid in the treatment of viral hepatitis.
7 Oct, 2022 | 14:22h | UTCSee complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Baveno VII – Renewing consensus in portal hypertension.
7 Oct, 2022 | 14:17h | UTCBaveno VII – Renewing consensus in portal hypertension – Journal of Hepatology
RCT | Trientine tetrahydrochloride noninferior to penicillamine for maintenance therapy in Wilson disease.
7 Oct, 2022 | 14:10h | UTCTrientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Schilsky et al – Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial https://t.co/OS0kh2EkM0#livertwitter #wilsonsdisease #wilsondisease pic.twitter.com/Grizm2uN7F
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 30, 2022
UEG and EAES rapid guideline | Recommendations on surgical management of gastroesophageal reflux disease.
6 Oct, 2022 | 13:45h | UTCCommentary: Updated GERD Guidelines Recommend Posterior Partial Fundoplication – HCP Live
Review | Alcohol and acute-on-chronic liver failure.
4 Oct, 2022 | 14:33h | UTCAlcohol and Acute-on-Chronic Liver Failure – Journal of Clinical and Experimental Hepatology
Related:
Acute-on-Chronic Liver Failure Clinical Guidelines – American Journal of Gastroenterology
Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU
Supplement | The role of liver transplantation in acute-on-chronic liver failure.
Podcast | Upper and lower GI bleed diagnosis and management.
4 Oct, 2022 | 14:33h | UTCUpper and Lower GI Bleed Diagnosis and Management – The Curbsiders
Podcast | Polyps, polypectomy & surveillance.
4 Oct, 2022 | 14:32h | UTCPolyps, polypectomy & surveillance with Dr. Jennifer Maranki – The Curbsiders
Cohort Study | Adenoma detection rate after a positive FIT is linked to the risk of interval postcolonoscopy colorectal cancer.
4 Oct, 2022 | 14:31h | UTCAdenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test–Based Screening: A Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries:
Adenoma Detection Rate Tied to CRC Risk After Positive FIT – HealthDay
Commentary on Twitter
New from @ErasmusMC: endoscopists performing colonoscopy in FIT-based screening programs should aim for higher ADRs compared w/ programs that use colonoscopy as primary screening intervention: https://t.co/Fob1gxXF1i pic.twitter.com/y6qoAkOrT9
— Annals of Int Med (@AnnalsofIM) September 30, 2022
Review | Acute kidney injury in patients with liver disease.
3 Oct, 2022 | 13:56h | UTC
Commentary on Twitter
AKI is commonly encountered in patients with decompensated cirrhosis, and it is associated with unfavorable outcomes. This article discusses tailoring management of AKI in patients with liver disease to the specific underlying etiology https://t.co/UVEeYBL8ff@VelezNephHepato pic.twitter.com/V5J8hBQyuw
— CJASN (@CJASN) September 27, 2022
European Crohn’s and Colitis Guidelines on sexuality, fertility, pregnancy, and lactation.
29 Sep, 2022 | 13:30h | UTC
Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients.
28 Sep, 2022 | 13:37h | UTC
Practice Guidance | A multidisciplinary approach to the diagnosis and management of Wilson Disease.
27 Sep, 2022 | 13:13h | UTC
RCT | Fecal microbiota transplantation better than standard of care for first or second Clostridioides difficile infection.
26 Sep, 2022 | 12:08h | UTCFaecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary: New FMT Trial Halted Due to Effectiveness – HCP Live
Commentary from the author on Twitter (thread – click for more)
Happy (and proud) to share EarlyFMT is now published in @Lancetgashep!#FMT after vancomycin outperforms vancomycin alone for 1st or 2nd #Cdiff infection!
90% FMT vs 33% vancomycin alone.Our thoughts behind the trial journey that started 5 years ago?https://t.co/91nS2TRY6Y pic.twitter.com/sFy6G3io39
— Simon MD Baunwall (@SMDBaunwall) September 22, 2022
Expert Practical Guidance | Functional abdominal cramping pain.
26 Sep, 2022 | 12:05h | UTCFunctional Abdominal Cramping Pain: Expert Practical Guidance – Journal of Clinical Gastroenterology
M-A of the association between new hypoglycemic agents and digestive diseases.
22 Sep, 2022 | 13:16h | UTCMeta-analysis of the association between new hypoglycemic agents and digestive diseases – Medicine
Commentary: Spotlight on digestive risks of newer diabetes drugs – ACP Gastroenterology
Review | Adrenal insufficiency in cirrhosis.
22 Sep, 2022 | 12:59h | UTCAdrenal Insufficiency in Cirrhosis – Journal of the Endocrine Society